1 / 10

Progress in the RNOH-IOMS Joint Academic Strategy

Trust Board July 2008. Progress in the RNOH-IOMS Joint Academic Strategy. David Marsh Professor of Clinical Orthopaedics, Institute of Orthopaedics and Musculoskeletal Science University College London Acting R&D Director, Royal National Orthopaedic Hospital Stanmore, UK.

duena
Télécharger la présentation

Progress in the RNOH-IOMS Joint Academic Strategy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trust Board July 2008 Progress in the RNOH-IOMS Joint Academic Strategy David Marsh Professor of Clinical Orthopaedics, Institute of Orthopaedics and Musculoskeletal Science University College London Acting R&D Director, Royal National Orthopaedic HospitalStanmore, UK

  2. Academic Health Science Centre CLINICAL EXCELLENCE,INTEGRATION RESEARCH EDUCATION • Joint Academic Plan: • integration of UG and PG education • R&D management into IOMS • Research strategy

  3. Research Strategy Health services research • Focused on musculoskeletal system but full spectrum Basic science Clinical trials Translational Experimental • Five themes, building on track record and patient needs • Innovative implant design • Cell therapy and tissue engineering • Disability and improvement of quality of life • Building the musculoskeletal evidence base • Sarcoma medicine

  4. UCL Dean and Research Vice-Provost Trust Board Institute of Orthopaedics and Musculoskeletal Science UCL and Partners Health Sciences Research Deanery Academic Research Board Education Committee Research Committee PPI group

  5. 05 06 07 08 09 10 11 12 Expenditure NHS R&D UCL Grant targetoverheads, contributions to salary, SCRF profit MRC stem cells in nonunion 300k Pfizer fracture accelerating drug 500k TSB grant 500k NIHR Applied Research Programme £2m

  6. Update • Research Committee • Clinical research facility • Cell therapy GMP facility • Funding

  7. Research Committee Rob Hurd Exec Team Nerina Bee Academic Business Development Joseph Fatukasi R&D Manager Simon Grange Clinical SL, Assistant R&D Director Richard Keen Research-active consultant Sue Marchetto Lead research nurse David Marsh Clinical Professor, R&D Director • Meeting fortnightly • Agenda evolving • Research governance: trial masterfiles, investigator files, GCP • Clinical research, pipeline • Links with LCRN, Deanery etc • First meeting of Academic Board planned for September

  8. Cell-based therapy • Previous clinical trials in ACI • Preclinical work on bone, collagen • Regenerative Medical Systems – UK • Lease signed for Centennial Park • Permanent staff coming in Sep • On stream Q1 - 2009 • Scientific Board • Translational teams: • Bone,Tendon,Cartilage

  9. MRC Translational Research Call • £241m extra, most on translational research • Bottlenecks • Pan-UCL bid going in • MRC Centre for Cell and Gene Therapy • Stanmore hopefully to contribute cell therapy in the musculoskeletal system

  10. Funding • Extra £196k from NIHR • Grants secured • MRC cells in impaction grafting • Vibration therapy in distraction osteogenesis • Instrumented IM nail • ITAP • ~15 trials in the pipeline • Grants in preparation Full economic costing

More Related